Advertisement
Topic: AS07. Late-Breaking Research| Volume 25, ISSUE 7, SUPPLEMENT , S359-S361, October 2022

PO257 / #737 CLINICAL TRIAL OF RESPONSIVE NEUROSTIMULATION OF THE AMYGDALA FOR TREATMENT-RESISTANT COMBAT POST-TRAUMATIC STRESS DISORDER

E-POSTER VIEWING
      Post-traumatic stress disorder (PTSD) is prevalent among veteran populations and is frequently unyielding to current evidence-based therapies, leading to a high incidence of severe treatment-resistant PTSD (TRPTSD)1,2. Deep brain stimulation offers precision, long-term application, and ongoing adjustability3. The aim of this current study (Clinicaltrials.gov NCT04152993) is to use responsive neurostimulation, targeting clinical symptoms based on simultaneously recorded alterations in fear circuitry in TRPTSD.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect